School Committee on Faculty Conduct, ORI found that Eric T. Fossel, Ph.D., former Harvard Medical School Associate Professor of Radiology at Beth Israel Hospital, committed scientific misconduct by reporting falsified research results in a Public Health Service (PHS) grant application.

Specifically, Dr. Fossel altered nuclear magnetic resonance (NMR) data in the Multicenter Breast Trial (MCBT) such that the NMR test, purporting to detect from a patient's blood sample a predisposition toward malignancy or a relapse, appeared to be more accurate, sensitive, and specific than was actually the case. Premised on these falsely reported results, Dr. Fossel proposed in a PHS grant application that the National Cancer Institute provide funds to complete the MCBT.

Dr. Fossel has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning May 9, 1996, to exclude himself from:

(1) any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations), and

(2) serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

No scientific publications were required to be corrected as part of this Agreement.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 96–14389 Filed 6–6–96; 8:45 am]

BILLING CODE 4160–17–P

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Teleconference Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 1, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.-5 p.m., June 24, 1996.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, ''Cooperative Agreements for Prevention Centers/ NCCDPHP—General Special Interest Projects.''

Contact Person for More Information: James E. Barrow, Deputy Director, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/ 488–5269.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers Program/ NCCDPHP—General Special Interest Projects, Panel Number 2, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.–5 p.m., June 25, 1996.

Place: NCCDPHP, CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, ''Cooperative Agreements for Prevention Centers/ NCCDPHP—General Special Interest Projects.''

Contact Person for More Information: Michael N. Waller, Program Manager, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/488–5292.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers Program/ NCCDPHP—General Special Interest Projects, Panel Number 3, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.–5 p.m., June 26, 1996.

Place: NCCDPHP, CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Considered: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, ''Cooperative Agreements for Prevention Centers/ NCCDPHP—General Special Interest Projects.''

Contact Person for More Information: Craig L. Leutzinger, Public Health Advisor, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/488–5304.

These meetings will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Dated: May 31, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–14381 Filed 6–6–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Advisory Committee Meeting; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is cancelling the meeting of the Science Board to the Food and Drug Administration scheduled for June 13, 1996, to provide time for the agency to continue its development of strategies to address toxicity, carcinogenicity, and biomaterials testing. The meeting was announced in the Federal Register of May 24, 1996 (61 FR 26187).

FOR FURTHER INFORMATION CONTACT: Susan A. Homire, Office of Science (HF–33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3340; or call the FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572) in the Washington, DC area, Science Board to the Food and Drug Administration, code 12603.

Dated: June 3, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–14388 Filed 6–06–96; 8:45 am]

BILLING CODE 4160–01–F

Memorandum of Understanding Between the Food and Drug Administration and the U.S. Department of Agriculture and the Russian Federation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the U.S. Department of Agriculture and

the Russian Federation. The purpose of the MOU is to exchange information and identify and implement technical cooperation and training activities for specialists for imported and domestic food in several areas.

DATES: The agreement became effective March 29, 1996.

FOR FURTHER INFORMATION CONTACT: Frank M. MacKeith, Center for Food Safety and Applied Nutrition (HFS–585), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–4045.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and memoranda of understanding between FDA and others shall be published in the Federal Register, the agency is publishing notice of this memorandum of understanding.

Dated: May 30, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

225–96–2005

Memorandum of Understanding Between the Food and Drug Administration of the Department of Health and Human Services of the United States of America and the Foreign Agricultural Service of the Department of Agriculture of the United States of America and the State Committee for Sanitary and Epidemiological Surveillance of the Russian Federation and the Committee of the Russian Federation on Standardization, Metrology and Certification Concerning Technical Cooperation and Information Exchange on Food Safety, Quality Control, and Labeling to Promote Public Health and Facilitate Trade

The Food and Drug Administration of the Department of Health and Human Services of the United States of America,
and
The Foreign Agricultural Service of the Department of Agriculture of the United States of America,
on the one hand; and
The State Committee for Sanitary and Epidemiological Surveillance (GOSKOMSANEPIDNADZOR) of the Russian Federation,
and
The Committee of the Russian Federation on Standardization, Metrology and Certification (GOSSTANDART),
on the other hand;

In keeping with the Agreement on Cooperation in the Fields of Public Health and Biomedical Research signed on January 14, 1994, by the Governments of the United States and the Russian Federation,

Desiring to strengthen the bonds of friendship and cooperation between the Russian Federation and the United States of America,

Recognizing that both the Russian Federation and the United States of America give special importance to the protection of public health by way of ensuring the safety, quality, and correct labeling of food,

Desiring to facilitate the trade of food between the Russian Federation and the United States of America,

And noting that increasing global trade of food and global trade agreements require that governments work to harmonize sanitary measures while not compromising food safety,

Have reached the following general understanding to guide their cooperation:

I. Objectives

The objectives of this Memorandum of Understanding are to:

A. Exchange information and identify and implement technical cooperation and training activities for specialists, including conducting workshops. These activities may be undertaken for imported and domestic food in the following areas: food safety, quality, labeling, laws and regulations; food examination, sanitation and control procedures and policies; risk assessment; analytical methodology; consumer food hygiene education; and other areas where additional information is needed concerning either side's food safety, quality control, and labeling systems.

B. Assist in ensuring transparency in the establishment and application of each side's sanitary measures.

C. Identify the systems used by each side and the type of documents that would be acceptable to each side to demonstrate the safety, quality, and labeling of food in accordance with the laws in the Russian Federation and the United States of America.

D. Provide confidence and build foundations for future agreements to ensure the safety, quality and correct labeling of food and to facilitate food trade for both the Russian Federation and the United States of America.

E. Develop and enhance systems for consideration and resolution of issues related to food safety, quality, and labeling to promote public health and facilitate trade between the Russian Federation and the United States of America.

F. Exchange information on the activities and deliberations of international food safety and quality standard-setting organizations, such as the Codex Alimentarius Commission. Facilitate the participation in such international organizations, and work within the framework of multilateral agreements toward harmonization of food requirements.

G. Provide distribution of information on each government's food import requirements to exporters in the Russian Federation and the United States of America.

II. Implementation

To achieve these goals, both sides intend to:

A. Meet and consult periodically to discuss emerging issues and to promote cooperation in carrying out the objectives of this Memorandum of Understanding. Meetings should alternate between the Russian Federation and the United States of America and will be held on mutually agreeable dates and at mutually agreeable places. Each side should designate a Chairperson. Together, they should develop meeting agendas and circulate appropriate information to participants prior to the meeting. Agenda topics and briefing papers should be identified as items for active discussion, information requests, or training needs. In addition, the Chairperson for the host country should be responsible for preparing and obtaining agreement on the minutes of the meeting.

B. Facilitate the import and export of food through the exchange of regulatory information on sanitary measures, requirements, and standards.

C. Work towards identifying the kinds of documents that demonstrate safety, quality, and correct labeling of food in accordance with the regulations and laws of the Russian Federation and the United States of America.

D. Identify and consider conducting technical cooperation and training programs for specialists from GOSKOMSANEPIDNADZOR, GOSSTANDART, and the Institute of Nutrition, Russian Academy of Medical Sciences.

E. Facilitate cooperation between the scientific centers of the Russian Federation and the United States of America, working in the area of food safety, quality, and labeling.

F. Provide information, as available, on the safety, quality, and labeling of food for export and on the manufacturers, producers or processors of this food.

All activities carried out under this Memorandum of Understanding are subject to the availability of appropriated funds, resources and personnel and are to be conducted in accordance with the laws of the Russian Federation and the United States of America.

III. Coordinators

Each participant in this Memorandum of Understanding should name a contact person to assist in logistical activities, and coordinate followup actions and implement the decisions reached during the meetings.

Activities under this Memorandum of Understanding will begin on the last date of signature of all participants. After the first year the participants plan to evaluate the Memorandum, thereafter, no less than once every 5 years. It may be amended by mutual written consent or terminated by any participant upon a 60-day written notice to the other participants.

Done in duplicate, in the Russian and English languages.

For the Department of Health and Human Services of the United States of America:

/s/ Donna E. Shalala
January 30, 1996
Washington, D.C.

For the Department of Agriculture of the United States of America: and Certification:

/s/ Richard E. Rominger
January 30, 1996
Washington, D.C.

For the Food and Drug Administration of the United States of America:

/s/ Mary Pendergast
January 30, 1996
Washington, D.C.

For the State Committee for Sanitary and Epidemiological Surveillance of the Russian Federation:

/s/ G. G. Onitshenko
January 30, 1996
Washington, D.C.

For the Committee of the Russian Federation on Standardization, Metrology, and Certification:

/s/ S. Bezverkhi
March 29, 1996
Moscow, Russian Federation

[FR Doc. 96–14387Filed 6–06–96; 8:45 am]
BILLING CODE 4160–01–F

National Institutes of Health

Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; Proposed Collection; Comment Request;

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

PROPOSED COLLECTION: *Title:* Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Type of Information Collection Request:* EXTENSION, OMB control number 0925–0407, expiration date September 30, 1996. *Need and Use of Information Collection:* This trial is designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers which currently cause an estimated 251,000 deaths annually in the U.S. The design is a two-armed randomized trial of men and women aged 55 to 74 at entry. The anticipated total sample size, after four and one half years of recruitment, is projected to be 148,000. The primary endpoint of the trial is cancer-specific mortality for each of the four cancer sites (prostate, lung, colorectal, and ovary). In addition, cancer incidence, stage shift, and case survival are to be monitored to help understand and explain results. Biologic prognostic characteristics of the cancers will be measured and correlated with mortality to determine the mortality predictive value of these intermediate endpoints. Basic demographic data, risk factor data for the four cancer sites and screening history data, as collected from all subjects at baseline, will be used to assure comparability between the screening and control groups and make appropriate adjustments in analysis. Further, demographic and risk factor information will be used to analyze the differential effectiveness of screening in high versus low risk individuals. *Frequency of Response:* On occasion. *Affected Public:* Individuals or households. *Type of Respondents:* Adult men and women. The annual reporting burden is as follows: *Estimated Number of Respondents:* 75,333; *Estimated Number of Responses per Respondent:* 1.7; *Average Burden Hours Per Response:* .573; and *Estimated Total Annual Burden Hours Requested:* 73,400. *The annualized cost to respondents is estimated at:* $734,290. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. John Gohagan, Chief, Early Detection Branch, EDCOP, National Cancer Institute, NIH, EPN Building, Room 330, 6130 Executive Boulevard, Bethesda, MD 20892–7346, or call non-toll-free number (301) 496–3982 or E-mail your request, including your address to:
gohaganj@dcpcepn.nci.nih.gov

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.

Dated: May 30, 1996.
Philip D. Amoruso,
Executive Officer, NCI.

[FR Doc. 96–14431 Filed 6–6–96; 8:45 am]
BILLING CODE 4140–01–M

National Center for Human Genome Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix), notice is hereby given of the following meetings of the National Center for Human Genome Research Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications and/or contract proposals.

Name of Committee: National Center for Human Genome Research Special Emphasis Panel 01.

Date: June 24, 1996.

Time: 7:00 p.m.

Place: NIH, Natcher (Building 45), Rooms G1/G2, 9000 Rockville Pike, Bethesda, Maryland

Contact Person: Ms. Linda Engel, Chief, Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

Name of Committee: National Center for Human Genome Research Special Emphasis Panel 02.

Date: June 25, 1996.

Time: 9:00 a.m.

Place: NIH, Natcher (Building 45), Rooms G1/G2, 9000 Rockville Pike, Bethesda, Maryland.

Contact Person: Ms. Linda Engel, Chief, Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

Name of Committee: National Center for Human Genome Research Special Emphasis Panel 03.

Date: June 25, 1996.

Time: 9:00 a.m.

Place: NIH, Natcher (Building 45), Rooms F1/F2, 9000 Rockville Pike, Bethesda, Maryland.

Contact Person: Ms. Linda Engel, Chief, Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or contract proposals, and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.